Adicet Bio Stock Current Liabilities
| ACET Stock | USD 1.06 0.01 0.95% |
Adicet Bio fundamentals help investors to digest information that contributes to Adicet Bio's financial success or failures. It also enables traders to predict the movement of Adicet Stock. The fundamental analysis module provides a way to measure Adicet Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adicet Bio stock.
Total Current Liabilities is likely to drop to about 18.3 M in 2024. Non Current Liabilities Total is likely to drop to about 16.9 M in 2024. Adicet | Current Liabilities |
Adicet Bio Company Current Liabilities Analysis
Adicet Bio's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Adicet Bio Current Liabilities | 98.91 M |
Most of Adicet Bio's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adicet Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Adicet Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Adicet Bio is extremely important. It helps to project a fair market value of Adicet Stock properly, considering its historical fundamentals such as Current Liabilities. Since Adicet Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adicet Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adicet Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Adicet Current Liabilities Historical Pattern
Today, most investors in Adicet Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adicet Bio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Adicet Bio current liabilities as a starting point in their analysis.
Adicet Bio Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Adicet Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Adicet Bio has a Current Liabilities of 98.91 M. This is 94.36% lower than that of the Health Care Providers & Services sector and 81.79% lower than that of the Health Care industry. The current liabilities for all United States stocks is 98.75% higher than that of the company.
Adicet Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adicet Bio's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adicet Bio could also be used in its relative valuation, which is a method of valuing Adicet Bio by comparing valuation metrics of similar companies.Adicet Bio is currently under evaluation in current liabilities category among its peers.
Adicet Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adicet Bio from analyzing Adicet Bio's financial statements. These drivers represent accounts that assess Adicet Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adicet Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 193.6M | 102.8M | 541.4M | 367.3M | 81.4M | 77.3M | |
| Enterprise Value | 297.0M | 40.2M | 284.8M | 130.6M | (57.4M) | (54.6M) |
Adicet Fundamentals
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (99.82 M) | ||||
| Shares Outstanding | 82.4 M | ||||
| Shares Owned By Insiders | 1.59 % | ||||
| Shares Owned By Institutions | 76.43 % | ||||
| Number Of Shares Shorted | 2.99 M | ||||
| Price To Earning | 36.84 X | ||||
| Price To Book | 0.40 X | ||||
| Price To Sales | 9.72 X | ||||
| Gross Profit | 24.99 M | ||||
| EBITDA | (136.53 M) | ||||
| Net Income | (142.66 M) | ||||
| Cash And Equivalents | 260.64 M | ||||
| Cash Per Share | 6.11 X | ||||
| Total Debt | 20.92 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 16.10 X | ||||
| Book Value Per Share | 3.93 X | ||||
| Cash Flow From Operations | (93.72 M) | ||||
| Short Ratio | 7.04 X | ||||
| Earnings Per Share | (1.70) X | ||||
| Price To Earnings To Growth | 0.82 X | ||||
| Target Price | 6.4 | ||||
| Number Of Employees | 143 | ||||
| Beta | 1.7 | ||||
| Market Capitalization | 84.05 M | ||||
| Total Asset | 207.29 M | ||||
| Retained Earnings | (380.77 M) | ||||
| Working Capital | 142.99 M | ||||
| Current Asset | 352.66 M | ||||
| Current Liabilities | 98.91 M | ||||
| Five Year Return | 3.23 % | ||||
| Net Asset | 207.29 M |
About Adicet Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adicet Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adicet Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adicet Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.